Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 32 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 2.9 to 1.
-
Busy address KBO
33 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
BIOCYTE BENELUX from Sint-Lambrechts-Woluwe, company number BE0730898265, closed financial year 2025 with a result of € 61 after tax. For that financial year BIOCYTE BENELUX recorded a gross margin of € 43,898 and equity of € -212,588. Compared with financial year 2024, the result moved from € -999 to € 61. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 15, 2026.
€ -212,588
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 61
▲ still € 999 loss in 2024
Profit after tax over the fiscal year.
€ 152,968
▲ 231% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -232,588.
People and assets in 2025
1
▼ 1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 41,184
▼ 70% vs 2024
€ 41,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 81
▼ 87% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 145,234
▼ 52% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 233,439 | € 220,738 | € 156,242 | € 43,898 | ▼ 72% |
| Profit after taxes | € -73,843 | € -89,476 | € -999 | € 61 | ▲ € 1,059 |
| Equity | € -122,174 | € -211,650 | € -212,649 | € -212,588 | |
| Total debts | € 409,518 | € 451,625 | € 361,023 | € 632,503 | ▲ 75% |
| Cash | € 24,539 | € 39,657 | € 46,272 | € 152,968 | ▲ 231% |
| Retained profit | € -142,174 | € -231,650 | € -232,649 | € -232,588 | |
| Balance sheet total | € 287,344 | € 239,975 | € 148,374 | € 419,914 | ▲ 183% |
| Employees (FTE) | 3.3 | 2.9 | 2 | 1 | ▼ 1 |
Key figures of BIOCYTE BENELUX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BIOCYTE BENELUX?
What happened at BIOCYTE BENELUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 61. filed late Source: NBB ↗
- Benjamin Francq stepped down as director. NBB
- Benjamin Francq became a director. NBB
- Bon Topco SAS became a director. NBB
- New establishment in Sint-Lambrechts-Woluwe. KBO
- Start of the company according to the CBE. KBO
In short
From € 73,843 loss in 2022 to € 61 profit in 2025.
Paid € 1,789 in corporate taxes since 2022.
Best year ever: 2025, with € 61 profit.
On average € 43,900 of value added per employee in 2025.
Management
The stake of ixX pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BIOCYTE BENELUXBehind BIOCYTE BENELUX is Bon Topco SAS. The shares are held by ixX pharma (100%).
Directors
According to the 2025 annual accounts
Director · represented by Nicolas Brodetsky
Also active at: Laboratoire Densmore Belgium, PONROY VITARMONYL BENELUX
since 2023
Benjamin Francq
Director
since 2024 · until 2026
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Veldkapelgaarde 30 box 1.30.30
1200 Sint-Lambrechts-Woluwe
Veldkapelgaarde 30
1200 Sint-Lambrechts-Woluwe
Active since 19 July 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 33 companies are registered at this address.
All companies at this address →Centre de Sante Universitaire de la Faculte de Medecine de l'Universite Catholique de Louvain (Section francophone)
€ 28,963 revenue · 2024
Services de Santé Mentale de l'UCL à Bruxelles
€ 704 revenue · 2024
Belgische Vereniging voor Medische, Informatica - Société belge d'Informatique médicale
Centre universitaire d'information sur les Professions médicales et-ou paramédicales
European Society of Surgical Oncology
€ 1.2 million revenue · 2025
+28 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0730.898.265
- VAT number
- BE 0730.898.265
- Registered office
- Veldkapelgaarde 30 bus 1.30.30, 1200 Sint-Lambrechts-Woluwe
- Names & denominations
- BIOCYTE BENELUX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 July 2019
- Peppol
- Active · Active since 30 Jul 2025
- Activities · NACE
Groothandel in parfumerieën en cosmetica
Handelsbemiddeling in de niet-gespecialiseerde groothandel
Vervaardiging van andere voedingsmiddelen, neg
Groothandel in andere voedingsmiddelen, neg